Ultragenyx Pharmaceutical (RARE) Earnings Date, Estimates & Call Transcripts → Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad) Free RARE Stock Alerts $45.11 +1.42 (+3.25%) (As of 04/23/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Earnings SummaryUpcoming Earnings DateMay. 2EstimatedActual EPS (Feb. 15) -$1.52 Beat By $0.13 Consensus EPS (Feb. 15) -$1.65 Read Call TranscriptListen to Call Get Ultragenyx Pharmaceutical Earnings AlertsEnter your email address below to receive the latest news and earnings results for RARE and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueRARE Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.RARE Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… Ultragenyx Pharmaceutical Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20242($1.49)($1.44)($1.47) Q2 20242($1.40)($1.37)($1.39) Q3 20242($1.38)($1.22)($1.30) Q4 20242($1.37)($1.19)($1.28) FY 20248($5.64)($5.22) ($5.43)RARE Earnings Date and InformationUltragenyx Pharmaceutical last posted its earnings data on February 15th, 2024. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.65) by $0.13. The business had revenue of $127.39 million for the quarter, compared to analysts' expectations of $119.38 million. Its revenue was up 23.3% compared to the same quarter last year. Ultragenyx Pharmaceutical has generated ($8.33) earnings per share over the last year (($8.33) diluted earnings per share). Earnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($6.36) to ($5.12) per share. Ultragenyx Pharmaceutical has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off prior year's report dates.Read More Ultragenyx Pharmaceutical Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/2/2024Estimated)------- 2/15/2024Q4 2023($1.65)($1.52)+$0.13($1.52)$119.38 million$127.39 million 11/2/2023Q3 2023($2.08)($2.23)($0.15)($2.23)$99.38 million$98.05 million8/3/2023Q2 2023($2.11)($2.25)($0.14)($2.25)$107.10 million$108.30 million 5/4/2023Q1 2023($1.97)($2.33)($0.36)($2.33)$103.90 million$100.50 million 2/16/2023Q4 2022($2.03)($2.16)($0.13)($2.16)$105.11 million$103.35 million 11/2/2022Q3 2022($2.29)($2.43)($0.14)($1.36)$98.76 million$90.70 million Get the Latest News and Ratings for RARE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. 7/28/2022Q2 2022($1.72)($2.26)($0.54)($2.26)$87.33 million$89.34 million 5/5/2022Q1 2022($1.76)($2.19)($0.43)($2.19)$84.25 million$79.94 million 2/10/2022Q4 2021($1.32)($1.79)($0.47)($1.79)$83.68 million$83.39 million 11/2/2021Q3 2021($1.43)($1.08)+$0.35($1.08)$78.16 million$81.65 million 8/1/2021Q2 2021($1.28)($1.81)($0.53)($1.09)$85.88 million$86.98 million 5/4/2021Q1 2021($1.25)($2.03)($0.78)($2.03)$77.21 million$99.40 million Ultragenyx Pharmaceutical Earnings - Frequently Asked Questions When is Ultragenyx Pharmaceutical's earnings date? Ultragenyx Pharmaceutical has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off last year's report dates. Learn more on RARE's earnings history. Did Ultragenyx Pharmaceutical beat their earnings estimates last quarter? In the previous quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) reported ($1.52) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.65) by $0.13. Learn more on analysts' earnings estimate vs. RARE's actual earnings. How can I listen to Ultragenyx Pharmaceutical's earnings conference call? The conference call for Ultragenyx Pharmaceutical's latest earnings report can be listened to online. Listen to Conference Call How can I read Ultragenyx Pharmaceutical's conference call transcript? The conference call transcript for Ultragenyx Pharmaceutical's latest earnings report can be read online. Read Transcript How much revenue does Ultragenyx Pharmaceutical generate each year? Ultragenyx Pharmaceutical (NASDAQ:RARE) has a recorded annual revenue of $434.25 million. How much profit does Ultragenyx Pharmaceutical generate each year? Ultragenyx Pharmaceutical (NASDAQ:RARE) has a recorded net income of -$606.64 million. RARE has generated -$8.33 earnings per share over the last four quarters. What is Ultragenyx Pharmaceutical's EPS forecast for next year? Ultragenyx Pharmaceutical's earnings are expected to grow from ($6.36) per share to ($5.12) per share in the next year. More Earnings Resources from MarketBeat Related Companies: BHVN Earnings PBH Earnings AXSM Earnings CBAY Earnings BHC Earnings XENE Earnings FOLD Earnings INSM Earnings IDYA Earnings ALKS Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Taiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted Applied Optoelectronics earnings dumper, pain now for gain later? This page (NASDAQ:RARE) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
